By Izzy Wood (Drug Target Review)2023-01-05T11:21:23
US researchers develop a dual-action cell therapy engineered to eliminate established tumours and train the immune system to eradicate primary tumour and prevent cancer’s recurrence.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-26T13:58:00Z
2023-03-30T12:35:58
Sponsored by Sartorius
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
2023-03-28T11:38:32
Sponsored by Bio-Techne
2025-10-22T14:00:00
Sponsored by Wuxi Biologics
2023-04-12T15:15:18
Sponsored by Cellistic
Site powered by Webvision Cloud